1-3 of 3
Maria Luisa Veronese
Close
Sort by
Journal Articles

The Efficacy of Vemurafenib in Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Preliminary Results from VE-Basket Study

David M. Hyman, MD, Eli Diamond, Vivek Subbiah, MD, Jean-Yves Blay, MD PhD, A. Craig Lockhart, Omar Abdel-Wahab, MD, Florin Sirzen, Maria Luisa Veronese, MD, Susan Frances Laserre, Elena Elez, Jose Baselga, MD PhD
Journal: Blood
Blood (2014) 124 (21): 635.
https://doi.org/10.1182/blood.V124.21.635.635
Published: 2014
Journal Articles

Expanding Nilotinib Access in Clinical Trials (ENACT) Study in Adult Patients (Pts) with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Blast Crisis (BC), Accelerated Phase (AP), or Chronic Phase (CP): Preliminary Safety Analysis.

Franck Nicolini, MD, Giuliana Alimena, MD, Haifa-Kathrin Al-Ali, MD, Andrey Zaritskey, Zhixiang Shen, MD, Saengsuree Jootar, MD, Graeme Smith, MD, Yanzhi Hsu, Maria Luisa Veronese, David A. Rizzieri
Journal: Blood
Blood (2007) 110 (11): 2960.
https://doi.org/10.1182/blood.V110.11.2960.2960
Published: 2007
Journal Articles

Cytogenetic Profile of Lymphoma of Follicle Mantle Lineage: Correlation With Clinicobiologic Features

Antonio Cuneo, Renato Bigoni, Gian Matteo Rigolin, Maria Grazia Roberti, Antonella Bardi, Nadia Piva, Raffaella Milani, Florencia Bullrich, Maria Luisa Veronese, Carlo Croce, Françoise Birg, Hartmut Döhner, Anne Hagemeijer, Gianluigi Castoldi
Journal: Blood
Blood (1999) 93 (4): 1372–1380.
https://doi.org/10.1182/blood.V93.4.1372
Published: 1999